Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting PLK1 potentiates the antitumor efficacy of EGFR-TKIs through inhibiting the JAK1/STAT3 pathway.

Cell death & disease - 15 Jan 2026

Li Cheng, Shi Shangxuan, Li Long, Wang Yafang, Yao Mingyue, Yu Chengcheng, Yu Chuwei, Xie Chengying

Abstract excerpt

Despite the rapid development of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in recent decades, resistance remains a significant challenge in managing advanced non-small cell lung cancer (NSCLC). Elucidating the mechanisms underlying EGFR-TKI resistance and developing novel strategies are therefore crucial. In this study, we investigated the role of polo-like kinase 1 (PLK1) in...

Read the complete abstract on PubMed

Topics

Humans
Animals
Mice
Cell Line
Polo-Like Kinase 1
Signal Transduction
ErbB Receptors

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Tyrosine Kinase Inhibitors

Antineoplastic Agents

Janus Kinase 1

STAT3 Transcription Factor

Carcinoma, Non-Small-Cell Lung

Lung Neoplasms

Mutation

Phosphorylation

Female

Mice, Inbred BALB C

Apoptosis

Source

Open in PubMed Open full text

Identifiers

PMID: 41539998
DOI: 10.1038/s41419-025-08220-9
PMCID: PMC12808168

Genes

EGFR
PLK1
STAT3
FGFR1
JAK1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 20 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting PLK1 potentiates the antitumor efficacy of EGFR-TKIs through inhibiting the JAK1/STAT3 pathway.PMID 41539998Read ↗

Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

The effect of PLK1 inhibitor in osimertinib resistant non-small cell lung carcinoma cells.Semantic proximity Read ↗

Analyses of expressions and prognostic values of Polo-like kinases in non-small cell lung cancer.Semantic proximity Read ↗

PIM1 kinase promotes EMT-associated osimertinib resistance via regulating GSK3β signaling pathway in EGFR-mutant non-small cell lung cancer.Semantic proximity Read ↗

New development of inhibitors targeting the PI3K/AKT/mTOR pathway in personalized treatment of non-small-cell lung cancer.Semantic proximity Read ↗

Emerging protein kinase inhibitors for non-small cell lung cancerSemantic proximity Read ↗

PIK3CA mutation as an acquired resistance driver to EGFR-TKIs in non-small cell lung cancer: Clinical challenges and opportunities.Semantic proximity Read ↗

The Emerging Role of Polo-Like Kinase 1 in Epithelial-Mesenchymal Transition and Tumor MetastasisSemantic proximity Read ↗

PLK-1 Targeted Inhibitors and Their Potential against TumorigenesisSemantic proximity Read ↗

A Novel Molecular Target in EGFR-mutant Lung Cancer Treated With the Combination of Osimertinib and Pemetrexed.Semantic proximity Read ↗

Polo-like kinase inhibitors: an emerging opportunity for cancer therapeuticsSemantic proximity Read ↗

In Silico and In Vitro Exploration of Poziotinib and Olmutinib Synergy in Lung Cancer: Role of hsa-miR-7-5p in Regulating Apoptotic Pathway Marker GenesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.